Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.

Bristol Myers Squibb (NYSE: BMY) belongs to an elite group. Only 2 different large-cap healthcare stocks connection higher dividend yields. Bristol Myers Squibb's juicy output of 4.3% is perfectly grabbing the attraction of galore income investors.

The drugmaker has paid a dividend for an awesome 94 consecutive years. Bristol Myers Squibb has accrued its dividend for 17 consecutive years. But is its dividend harmless now? Here's what investors request to know.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

The coverage, the cliff, and the catalysts

Let's commencement with immoderate bully news. Bristol Myers Squibb's dividend payout ratio presently stands astatine 70%. While a little ratio is preferable, the pharma giant's net are much than capable to screen its dividend close now.

Sure, Bristol Myers Squibb didn't make capable escaped currency travel successful the archetypal 4th of 2026 to money its dividend program. However, this reflected the antagonistic interaction of little Eliquis pricing that should beryllium mostly offset aboriginal this twelvemonth by little rebate payments.

The atrocious quality for Bristol Myers Squibb's dividend, though, is the company's looming patent cliff. Blockbuster drugs Eliquis and Opdivo suffer patent exclusivity successful 2028. These 2 products generated astir fractional of Bristol Myers Squibb's full gross past year.

However, the patent cliff is lone portion of the story. Bristol Myers Squibb's maturation portfolio present represents the bulk of the company's full revenue. Sales for newer products, including crab immunotherapies Breyanzi and Opdualag, autoimmune illness cause Sotyktu, and schizophrenia therapy Cobenfy, are increasing rapidly. The drugmaker's pipeline besides features astir 50 programs successful development, respective of which clasp the imaginable to beryllium maturation catalysts.

The verdict

My instrumentality is that Bristol Myers Squibb's 4.3% dividend output is safe, astatine slightest for the adjacent mates of years. What astir beyond that point? I'm cautiously optimistic.

I expect that Bristol Myers Squibb's maturation portfolio volition make capable gross that the institution volition beryllium capable to debar cutting its dividend aboriginal this decade. It wouldn't astonishment me, though, if the streak of dividend increases comes to a screeching halt.

That said, it's inactive imaginable that the patent cliff could wounded Bristol Myers Squibb worse than I'm anticipating. The drugmaker's indebtedness besides totaled $44.5 cardinal astatine the extremity of the archetypal 4th of 2026. That's manageable but coud go problematic if the maturation portfolio and pipeline don't present arsenic I deliberation they will.